A review of myasthenia gravis: Pathogenesis, clinical features and treatment

Current Anaesthesia and Critical Care

Volumn 18, Issue 1, 2007, Pages 15-23

  Turner, Chris ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Autoimmunity; Immunosuppression; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ATROPINE; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID DERIVATIVE; CURARE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPHENOXYLATE; EDROPHONIUM CHLORIDE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LOCAL ANESTHETIC AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; NICOTINIC RECEPTOR; PENICILLAMINE; PHENYTOIN; PROCAINAMIDE; PROPANTHELINE BROMIDE; PYRIDOSTIGMINE; QUININE; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG;

ABDOMINAL PAIN; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BOTULISM; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL DISORDER; CONGENITAL MYASTHENIC SYNDROME; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; EATON LAMBERT SYNDROME; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; IMMUNOPATHOGENESIS; LIVER TOXICITY; LOW DRUG DOSE; MANAGED CARE; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOPATHY; NEPHROTOXICITY; NEUROANATOMY; NEUROLOGIC DISEASE; NEUROMUSCULAR SYNAPSE; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMAPHERESIS; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROGNOSIS; PTOSIS; RESPIRATORY FAILURE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THYMECTOMY; THYMOMA; THYMUS; UNSPECIFIED SIDE EFFECT;

EID: 34250801502     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2007.01.006     Document Type: Review

References (35)

1. Pritchard E.A.B. The use of "Prostigmin" in the treatment of myasthenia gravis. Lancet i (1935) 432-434
2. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 11 (1976) 1054-1059
3. MacDonald B.K., Cockerell O.C., Sander J.W., and Shorvon S.D. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123 Pt 4 (2000) 665-676
4. Vincent A., Bowen J., Newsom-Davis J., and McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2 2 (2003) 99-106
5. Osserman K.E. Myasthenia gravis (1958), Grune and Stratton, New York
6. Penn A.S., Low B.W., Jaffe I.A., Luo L., and Jacques J.J. Drug-induced autoimmune myasthenia gravis. Ann N Y Acad Sci 841 (1998) 433-449
7. Lindstrom J.M. Acetylcholine receptors and myasthenia. Muscle Nerve 23 4 (2000) 453-477
8. Vincent A., Beeson D., and Lang B. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur J Biochem 267 23 (2000) 6717-6728
9. Thanvi B.R., and Lo T.C. Update on myasthenia gravis. Postgrad Med J 80 950 (2004) 690-700
10. Drachman D.B., de Silva S., Ramsay D., and Pestronk A. Humoral pathogenesis of myasthenia gravis. Ann N Y Acad Sci 505 (1987) 90-105
11. Newsom-Davis J., Harcourt G., Sommer N., Beeson D., Willcox N., and Rothbard J.B. T-cell reactivity in myasthenia gravis. J Autoimmun 2 Suppl (1989) 101-108
12. Jaretzki A., Steinglass K.M., and Sonett J.R. Thymectomy in the management of myasthenia gravis. Semin Neurol 24 1 (2004) 49-62
13. Scherer K., Bedlack R.S., and Simel D.L. Does this patient have myasthenia gravis?. JAMA 293 15 (2005) 1906-1914
14. Nicolle M.W. Myasthenia gravis. Neurologist 8 1 (2002) 2-21
15. Osserman K.E., and Teng P. Studies in myasthenia gravis-a rapid diagnostic test; further progress with edrophonium (tensilon) chloride. J Am Med Assoc 160 3 (1956) 153-155
16. Vincent A., and Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48 12 (1985) 1246-1252
17. Oh S.J., Kim D.E., Kuruoglu R., Bradley R.J., and Dwyer D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 15 6 (1992) 720-724
18. Somnier F.E., and Trojaborg W. Neurophysiological evaluation in myasthenia gravis. A comprehensive study of a complete patient population. Electroencephalogr Clin Neurophysiol 89 2 (1993) 73-87
19. Schneider-Gold C., Gajdos P., Toyka K.V., and Hohlfeld R.R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 18 2 (2005) CD002828
20. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 4 (2004) 484-505
21. Palace J., Newsom-Davis J., and Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 6 (1998) 1778-1783
22. Tindall R.S., Phillips J.T., Rollins J.A., Wells L., and Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 681 (1993) 539-551
23. Kawaguchi N., Yoshiyama Y., Nemoto Y., Munakata S., Fukutake T., and Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20 8 (2004) 1269-1273
24. Chiu H.C., Chen W.H., and Yeh J.H. The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 4 4 (2000) 291-295
25. Dalakas M.C. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102 3 (2004) 177-193
26. Gajdos P., Chevret S., Clair B., Tranchant C., and Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41 6 (1997) 789-796
27. Budde J.M., Morris C.D., Gal A.A., Mansour K.A., and Miller Jr. J.I. Predictors of outcome in thymectomy for myasthenia gravis. Ann Thorac Surg 72 1 (2001) 197-202
28. Remes-Troche J.M., Tellez-Zenteno J.F., Estanol B., Garduno-Espinoza J., and Garcia-Ramos G. Thymectomy in myasthenia gravis: response, complications, and associated conditions. Arch Med Res 33 6 (2002) 545-551
29. Hoff J.M., Daltveit A.K., and Gilhus N.E. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 61 10 (2003) 1362-1366
30. Jackson C.E. Patient page. The effect of myasthenia gravis on pregnancy and the newborn. Neurology 61 10 (2003) 1459-1460
31. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 14 Suppl 1 (2005) s46-s49
32. Wylam M.E., Anderson P.M., Kuntz N.L., and Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 143 5 (2003) 674-677
33. Tuzun E., Meriggioli M.N., Rowin J., Yang H., and Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun 24 3 (2005) 261-268
34. Wang P., Zuo C., Tian J., et al. CT-guided percutaneous ethanol injection of the thymus for treatment of myasthenia gravis. AJR Am J Roentgenol 181 3 (2003) 721-724
35. Papanastasiou D., Poulas K., Kokla A., and Tzartos S.J. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 104 2 (2000) 124-132